Abstract
Multiple sclerosis (MS) is a progressive inflammatory demyelinating disease in the central nervous system (CNS). Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. Melatonin secretion peaks at 2 AM, concomitant with the time at which the muscles are resting and the body is exerting its antioxidant activity. The current study was designed to investigate combination treatment of baclofen, a muscle relaxant drug, and melatonin in EAE mice. Results showed that melatonin (Mel) alone or in combination with baclofen (Bac + Mel) reduced clinical scores and demyelination by significantly increasing myelin oligodendrocyte glycoprotein (MOG) levels, a marker for mature oligodendrocytes, compared to EAE mice. Moreover, Mel or Bac + Mel therapy caused a significant increase in IL-4 serum levels, an anti-inflammatory cytokine, whereas IFN-γ serum levels, a pro-inflammatory cytokine, were significantly reduced. On the other hand, Mel or Bac + Mel caused a significant reduction in malondialdehyde (MDA) levels, a marker of oxidative stress, in comparison to EAE mice. In contrast, the activity of antioxidant enzymes catalase (CAT) and superoxide dismutase (SOD) was signifi...Continue Reading
References
Jun 8, 1989·The New England Journal of Medicine·R D PennJ S Kroin
Jan 1, 1995·Journal of Pineal Research·R J ReiterD Acuña-Castroviejo
Jul 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·P Brown
Feb 1, 1993·The International Journal of Neuroscience·R Sandyk
Nov 24, 1993·JAMA : the Journal of the American Medical Association·A L AlbrightJ Janosky
Aug 15, 1993·Experientia·R J Reiter
Jan 1, 1997·Annual Review of Immunology·S L Constant, K Bottomly
Aug 1, 1997·Journal of Neurology, Neurosurgery, and Psychiatry·B MiddelR Stewart
Apr 20, 2001·Laboratory Investigation; a Journal of Technical Methods and Pathology·D M WingerchukJ H Noseworthy
Oct 26, 2005·Journal of Autoimmunity·Wei LiuNing-Ling Sun
Sep 3, 2008·Immunopharmacology and Immunotoxicology·Abbas Mirshafiey, Monireh Mohsenzadegan
Oct 17, 2008·Physiological Reviews·Scott K Powers, Malcolm J Jackson
Sep 23, 2009·PloS One·Paul OlivierOlivier Baud
Dec 6, 2011·Journal of the Neurological Sciences·Lena MelamudAriel Miller
Aug 29, 2012·ISRN Neurology·A HilliardG Giovannoni
Aug 24, 2013·Journal of Neuroimmunology·Faye E NasholdColleen E Hayes
Oct 8, 2013·BMC Geriatrics·Melanie J Sullivan-Gunn, Paul A Lewandowski
Jan 16, 2014·Korean journal of anesthesiology·Ji Seon JeongMi Ae Jeong
Jun 30, 2014·Neurochemical Research·Monika Adamczyk-SowaMarcin Hartel
Jul 3, 2015·Brain, Behavior, and Immunity·Nuria Álvarez-SánchezAntonio Carrillo-Vico
Sep 12, 2015·Cell·Mauricio F FarezJorge Correale
Dec 19, 2015·Life Sciences·Solaleh EmamgholipourMohammad Ansari
Jan 7, 2016·International Immunopharmacology·Shyi-Jou ChenHuey-Kang Sytwu
Oct 4, 2016·Clinical and Experimental Pharmacology & Physiology·Majid GhareghaniHeibatollah Sadeghi
Dec 18, 2016·Cellular and Molecular Neurobiology·Majid GhareghaniAmir Ghanbari
Jul 9, 2017·Scientific Reports·Majid GhareghaniAmir Ghanbari
Citations
Jul 28, 2018·Immunopharmacology and Immunotoxicology·Suat KamisliCemal Ozcan
Dec 18, 2019·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Charalampos Skarlis, Maria Anagnostouli
Mar 16, 2019·Frontiers in Pharmacology·Majid GhareghaniKazem Zibara
May 6, 2019·Clinical Drug Investigation·Mahshid Yeganeh SalehpourMohammad Hosein Farzaei
Nov 3, 2020·Aging·Ting ChangZhuyi Li
Oct 3, 2020·Experimental Neurology·Frederique WietersMarkus Aswendt
May 14, 2021·Frontiers in Pharmacology·Monika Dmitrzak-WeglarzJoanna Pawlak
May 29, 2021·Translational Neuroscience·Majid GhareghaniKazem Zibara